Short answer
Tarsus Pharmaceuticals, Inc. (TARS) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Tarsus Pharmaceuticals’ third-quarter and nine-month results through September 30, 2026.
Tarsus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Tarsus Pharmaceuticals’ third-quarter and nine-month results through September 30, 2026
- Exhibit 99.1 contains the company’s operating results and accompanying financial details
Item EX-99.1 · Exhibit EX-99.1
- Q3 product sales $194.6M, up approximately 64% year over year, confirming strong XDEMVY commercial momentum
- XDEMVY surpassed one million bottles dispensed and $1B cumulative net sales since launch
- Refills represented approximately 20% of Q3 prescriptions, supporting growing retreatment and recurring demand
- Net loss $668.3M, driven by $632.2M acquired IPR&D expenses from iRenix and Alkeus acquisitions
- Cash, cash equivalents and marketable securities $309.6M, while acquisitions added $85.7M of contingent consideration liabilities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tarsus Pharmaceuticals, Inc. 8-K filings
Get the next TARS 8-K as it lands
Follow TARS for push alerts, or ask the research agent what this filing means.